Revolution Medicines, Inc. (RVMD)

Revolution Medicines Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	333.55	543.06	696.15	161.41	108.5	104.27
Short-Term Investments	1,769	1,746	1,157	483.53	468.56	336.47
Cash & Short-Term Investments	2,103	2,289	1,853	644.94	577.05	440.74
Cash Growth	23.43%	23.55%	187.31%	11.77%	30.93%	259.03%
Receivables	-	-	1.25	4.67	5.93	6.39
Prepaid Expenses	31.91	38.33	25.07	10.57	6.79	6.99
Total Current Assets	2,135	2,328	1,879	660.19	589.77	454.12
Property, Plant & Equipment	142.93	141.82	100.01	73.74	71.24	36.34
Goodwill	14.61	14.61	14.61	14.61	14.61	14.61
Other Intangible Assets	56.4	56.67	57.74	58.81	59.88	60.95
Long-Term Deferred Charges	-	-	-	-	0.5	-
Other Long-Term Assets	16.83	17.57	10.06	4.59	2	1.39
Total Assets	2,365	2,558	2,062	811.93	737.99	567.4
Accounts Payable	47.51	54.43	61.79	21.31	14.06	12.61
Accrued Expenses	97.46	96.03	70.8	28.94	27.41	18.69
Current Portion of Leases	12.98	12.87	7.37	6.77	6.21	3.67
Current Unearned Revenue	-	-	-	4.46	12.36	12.11
Other Current Liabilities	0.65	0.58	3.9	0.51	0.31	0.1
Total Current Liabilities	158.6	163.91	143.85	61.98	60.35	47.18
Long-Term Leases	121.36	122.97	80.58	57.43	60.42	28.99
Long-Term Unearned Revenue	-	-	-	-	6.57	8.48
Long-Term Deferred Tax Liabilities	2.35	2.35	3.12	7.03	7.44	7.44
Other Long-Term Liabilities	4.89	3.86	7.97	0.3	0.63	0.63
Total Liabilities	287.2	293.1	235.51	126.74	135.42	92.73
Common Stock	0.02	0.02	0.02	0.01	0.01	0.01
Additional Paid-In Capital	4,028	4,002	2,963	1,388	1,056	740.1
Retained Earnings	-1,951	-1,738	-1,138	-701.34	-452.64	-265.55
Comprehensive Income & Other	1.71	1.32	0.54	-1.78	-0.38	0.12
Total Common Equity	2,078	2,265	1,826	685.19	602.57	474.68
Shareholders' Equity	2,078	2,265	1,826	685.19	602.57	474.68
Total Liabilities & Equity	2,365	2,558	2,062	811.93	737.99	567.4
Total Debt	134.34	135.84	87.94	64.21	66.63	32.66
Net Cash (Debt)	1,968	2,153	1,765	580.74	510.42	408.08
Net Cash Growth	21.84%	22.01%	203.93%	13.78%	25.08%	232.97%
Net Cash Per Share	11.34	12.84	15.60	7.20	7.01	7.44
Filing Date Shares Outstanding	186.27	185.91	164.69	90.49	74.19	73.38
Total Common Shares Outstanding	186.26	185.9	164.67	90.41	74.14	66.6
Working Capital	1,976	2,164	1,735	598.2	529.42	406.95
Book Value Per Share	11.16	12.19	11.09	7.58	8.13	7.13
Tangible Book Value	2,007	2,194	1,754	611.77	528.08	399.12
Tangible Book Value Per Share	10.78	11.80	10.65	6.77	7.12	5.99
Machinery	32.79	31.44	28.09	21.74	14.98	11.6
Construction In Progress	3.17	0.39	0.51	-	0.13	1.98
Leasehold Improvements	14.57	14.28	11.95	11.4	7.25	3.39

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q